EPO and anemia: Triple therapy is associated with a 20% increase in the incidence of treatment-related anemia compared with the former standard PegIFN/RBV therapy, and, according to a recent interim analysis of patients who underwent TVR therapy after OLT, 77% of all patients require EPO administration under TVR therapy [33–35].